Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen Names Invitrogen Alumnus to New Position; ChemGenex Hires New Cancer VP; Micronics Adds a Director; and Others

NEW YORK (GenomeWeb News) — Lentigen has named Adam Sachs to the newly created position of president of commercial operations, where he will lead efforts to market the firm’s lentiviral platform, the company said.
Sachs comes to Lentigen having spent 15 years in the biotech field, most recently as a molecular biology product development executive at Life Technologies, which is now Invitrogen.
Sachs also was director of manufacturing at Qiagen and vice president of operations at OriGene Technologies.  

ChemGenex has appointed Ian Nisbet vice president of oncology, the company said.
Nisbet comes ChemGenex from Millennium Pharmaceuticals, where he worked at obtaining US Food and Drug Administration approval for Millennium’s oncology treatments.

The Analytical and Life Science Systems Association, a trade group for product makers and marketers in the life sciences, has appointed Eksigent president and CEO David Weber to its board of directors, Eksigent said.
Before joining Eksigent Weber served as vice president of global marketing and business development for Stratagene and was president of the Americas at Amersham Biosciences.

Micronics has named Albert Luderer to its board of directors, the Redmond, Wash.-based diagnostics company said. Luderer is CEO at Biotrove, and has worked in medical diagnostics and technology for two decades.
In his career, Luderer has been president and COO at Biomerieux and had been a vice president of technology development at Boehringer Mannheim.

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.